Near-Infrared Photoimmunotherapy Using a Protein Mimetic for EGFR-Positive Salivary Gland Cancer. [PDF]
Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer therapy based on a monoclonal antibody (mAb) conjugated to a photosensitizer (IR700Dye). The conjugate can be activated by near-infrared light irradiation, causing necrotic cell death with high
Yamaguchi H +8 more
europepmc +2 more sources
Elimination of radiation-induced senescent cancer cells and stromal cells in vitro by near-infrared photoimmunotherapy. [PDF]
Suzuki M +3 more
europepmc +1 more source
Preserved host immunity with intercellular adhesion molecule-1 (ICAM-1)-targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of triple-negative breast cancer and other malignancies. [PDF]
Takao S +8 more
europepmc +1 more source
Near Infrared Photoimmunotherapy for Locoregionally Recurrent Oropharyngeal Squamous Cell Carcinoma at Tongue Base After Chemoradiotherapy: A Case Report and Literature Review. [PDF]
Tamagawa S +4 more
europepmc +1 more source
Near-infrared photoimmunotherapy targeting Nectin-4 in a preclinical model of bladder cancer. [PDF]
Fukushima H +9 more
europepmc +1 more source
Near Infrared Photoimmunotherapy; A Review of Targets for Cancer Therapy [PDF]
Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed cancer treatment that uses an antibody-photoabsorber (IRDye700DX) conjugate (APC) that is activated by NIR light irradiation.
Hiroaki Wakiyama +2 more
exaly +4 more sources
Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the Local Control of Solid Cancers: Challenges and Potentials for Human Applications [PDF]
Near-InfraRed PhotoImmunoTherapy (NIR-PIT) is a novel cancer-targeted treatment effected by a chemical conjugation between a photosensitiser (e.g. the NIR phthalocyanine dye IRDye700DX) and a cancer-targeting moiety (e.g.
Marta Barisa +2 more
exaly +3 more sources
Near-Infrared Photoimmunotherapy for the Treatment of Skin Disorders
Expert Opinion on Biological Therapy, 2022Mauro Alaibac +2 more
exaly

